Brown Brothers Harriman & Co. Has $20.35 Million Stake in Eli Lilly and Company (NYSE:LLY)

Brown Brothers Harriman & Co. increased its position in Eli Lilly and Company (NYSE:LLY) by 21.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 26,358 shares of the company’s stock after purchasing an additional 4,690 shares during the quarter. Brown Brothers Harriman & Co.’s holdings in Eli Lilly and Company were worth $20,348,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. RiverFront Investment Group LLC increased its stake in Eli Lilly and Company by 99.3% in the fourth quarter. RiverFront Investment Group LLC now owns 5,156 shares of the company’s stock valued at $3,980,000 after acquiring an additional 2,569 shares during the period. Vertex Planning Partners LLC raised its holdings in shares of Eli Lilly and Company by 21.6% in the 4th quarter. Vertex Planning Partners LLC now owns 597 shares of the company’s stock worth $461,000 after buying an additional 106 shares in the last quarter. Orion Portfolio Solutions LLC lifted its position in shares of Eli Lilly and Company by 13.9% during the 4th quarter. Orion Portfolio Solutions LLC now owns 43,569 shares of the company’s stock worth $33,635,000 after buying an additional 5,327 shares during the period. Pictet Asset Management Holding SA grew its position in Eli Lilly and Company by 6.6% in the fourth quarter. Pictet Asset Management Holding SA now owns 662,370 shares of the company’s stock valued at $511,350,000 after acquiring an additional 40,778 shares during the period. Finally, Nomura Asset Management Co. Ltd. raised its stake in Eli Lilly and Company by 2.6% during the fourth quarter. Nomura Asset Management Co. Ltd. now owns 352,620 shares of the company’s stock worth $272,223,000 after acquiring an additional 9,034 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.2 %

Shares of Eli Lilly and Company stock opened at $820.30 on Friday. The business has a fifty day simple moving average of $844.31 and a 200 day simple moving average of $836.82. The stock has a market cap of $777.78 billion, a PE ratio of 70.05, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 12 month low of $711.40 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company announced that its board has initiated a share repurchase program on Monday, December 9th that allows the company to buyback $15.00 billion in shares. This buyback authorization allows the company to repurchase up to 2% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s board believes its shares are undervalued.

Analysts Set New Price Targets

Several equities research analysts have recently commented on LLY shares. Berenberg Bank set a $970.00 target price on shares of Eli Lilly and Company in a research note on Thursday, January 16th. Bank of America restated a “buy” rating and set a $997.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Citigroup dropped their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Finally, Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,009.72.

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.